Dr. Wiestner Discusses Findings From the Phase III HELIOS Trial
June 19th 2015Adrian Wiestner, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Services, discusses findings from the phase III HELIOS trial, which explored the addition of ibrutinib to bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia.
Ibrutinib, Ublituximab, TGR-1202 Triplet Active in Relapsed B-Cell Malignancies
June 19th 2015A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.
Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLL
June 19th 2015Susan M. O'Brien, MD, associate director, Clinical Science Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, Chao Family Comprehensive Cancer Center, University of California at Irvine, discusses the use of ibrutinib and idealisib in chronic lymphocytic leukemia (CLL).
SYK Inhibitor TAK-659 Shows Promising Results in Lymphoid Malignancies
June 18th 2015TAK-659, an inhibitor of spleen tyrosine kinase, showed early signs of antitumor activity in patients with lymphoma, with two expansion arms planned for patients with diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCD
June 18th 2015Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.
Dr. Adrian Wiestner on RESONATE II Trial
June 17th 2015Adrian Wiestner, MD, PhD, Senior Investigator, Laboratory of Lymphoid Malignancies, National Institutes of Health, National Heart, Lung, and Blood Services discusses the findings of the RESONATE II trial, which looked at chlorambucil versus ibrutinib as first-line therapy in patients older than 65 with chronic lymphocytic leukemia (CLL).